Thursday, November 22, 2018 11:41:18 AM
UK funds efforts to make country a leader in cell and gene therapy
Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy Kymriah.
The three companies will share a £4.3m Digitalisation of Medicines Manufacturing fund from the government Department for Business, Enterprise and Industrial Strategy, (BEIS) which aims to create more efficient and innovative methods for manufacturing medicines.
Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.
HTTp://www.pmlive.com/pharma_news/digital_tech_from_autolous_and_oxford_biomedica_to_speed_advanced_therapies_1262473
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM